



# BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.  
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com  
CIN : L24294 TN1995PLC030698

Date: November 12, 2021

To,

Listing Department,  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400 001  
**Scrip Code:** 532989

Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**Symbol – BAFNAPH**

**Subject: Outcome of Meeting of the Board of Directors of Bafna Pharmaceuticals Limited ("the Company") in terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") as amended, this is to inform you that the Board of Directors ("Board") of the Company, had at its meeting held today i.e. Friday, November 12, 2021, the Board has decided the following matters:

1. Approved the un - audited financial results of the Company for the quarter /half year ended September 30, 2021. Please find attached Limited Review Report from the Statutory Auditor.
2. Statutory Auditors comments along with Management's Reply:

<b>Statutory Auditor's Comment</b>	<b>Management's Reply</b>
<i>(a) Valuation of Work-in-progress and Finished goods as on 30th September 2021 not computed as per principles laid down in IND AS 2,</i>	Due to technical delays in the updation in line with the production process in the SAP system, the Company has not valued inventories on the basis of IND AS 2 principles. The same would be streamlined to comply with the standard by the end of Current Financial year ending, and the resultant impact if any would be quantified appropriately .
<i>(b) Unresolved mismatch in respect of ITC (Input tax credit) between books of accounts and GSTR2A, the taxable value of which was Rs 53 lakhs,</i>	The Net unavailed Input Credits were identified and necessary rectification will be done. The Company is continuously following with the vendor and we are yet to receive any reply from them.
<i>c) SAP system not being fully online at Grantylon factory in respect of Stores/production processes</i>	There are some technical delays in the updation of production process in SAP which we are confident to complete by the end of Current Financial Year.
<i>(d) Fixed Asset register not being maintained in SAP as prescribed under Schedule II of the Companies Act besides non- compliance in respect of IND AS 16</i>	The company has already commenced the updation process as required and are confident to complete by the end of the ensuing quarter.





# BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.  
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com  
CIN : L24294 TN1995PLC030698

### 3. Raising of funds by way of offer and issue of equity shares to the existing shareholders of the Company on a rights basis (Rights Issue) for an aggregate amount upto INR 50 Crore.

The Board has constituted a Rights Issue Committee of Directors for the above purpose and has authorised the Committee to determine the terms of the Rights Issue including the quantum of issue, rights entitlement ratio, issue price, issue size, book closure or record date, entitlement timing of the issue, appointment of intermediaries, etc., in consultation with the Lead Manager to the Right Issue and to decide all other matters relating to the Right Issue. Such details shall be informed and/or announced in due course as and when decided or required, as per applicable statutory provisions and depending upon the market conditions. The above proposal to issue of shares shall be subject to necessary approvals, confirmations and consents as may be necessary and in compliance with applicable law including the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013 and the Rules made there under and as amended.

The proposed Rights Issue will be a step towards meeting with the Minimum Public Shareholding requirements and is one of the prescribed methods in accordance with SEBI Circular No. CIR/CFD/CMD/14/2015 dated November 30, 2015, as amended. Accordingly, the Promoter may not participate in the proposed Rights Issue.

The meeting commenced as IST 11.00 am and concluded at ~~12.00~~pm.

Please take note of the same in your record and acknowledge the receipt of the same.

Thanking you,

Yours faithfully,

For Bafna Pharmaceuticals Limited

Jitendra Kumar Pal  
Company Secretary & Compliance Officer



**BAFNA PHARMACEUTICALS LIMITED ( CIN L24294TN1995PLC030698)**

Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Unaudited Standalone Financial Results for the Quarter and Half Year Ended 30 th September 2021

PART I

(Rs. In Lakhs) except EPS

Sl.No	Particulars	3 months ended	Previous 3	Corresponding 3	Year to Date	Corresponding	For the Previous
		(30-09-2021)	months ended	months ended	for the Period	Year to date	Year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue From operations	2,843.92	2,125.86	1,519.96	4,969.78	3,190.21	7,121.79
II	Other Income	17.64	17.00	22.71	34.64	40.26	74.93
III	<b>Total Income (I+II)</b>	<b>2,861.56</b>	<b>2,142.87</b>	<b>1,542.67</b>	<b>5,004.43</b>	<b>3,230.47</b>	<b>7,196.72</b>
IV	<b>EXPENSES</b>						
a)	Cost of materials consumed	1,841.87	1,361.65	1,044.27	3,203.52	2,120.46	4,250.95
b)	Purchases of Stock-in-Trade	-	-	-	-	-	-
c)	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	(223.95)	(53.71)	(51.91)	(277.66)	42.25	294.60
d)	Employee benefits expense	389.88	325.99	301.51	715.87	480.88	1,198.41
e)	Finance costs	10.91	10.61	2.12	21.52	3.77	74.19
f)	Depreciation and amortization expenses	142.28	146.09	101.36	288.37	196.09	447.82
g)	Other expenses	266.41	143.54	97.46	409.95	158.00	348.07
	<b>Total expenses (IV)</b>	<b>2,427.40</b>	<b>1,934.17</b>	<b>1,494.81</b>	<b>4,361.57</b>	<b>3,001.45</b>	<b>6,614.05</b>
V	<b>Profit/(loss) before exceptional items and tax (I-IV)</b>	<b>434.16</b>	<b>208.70</b>	<b>47.87</b>	<b>642.86</b>	<b>229.03</b>	<b>582.67</b>
VI	Exceptional Items	196.53	-	-	196.53	-	-
VII	<b>Profit/ (loss) before exceptions items and tax(V-VI)</b>	<b>237.63</b>	<b>208.70</b>	<b>47.87</b>	<b>446.33</b>	<b>229.03</b>	<b>582.67</b>
VIII	<b>Tax expense:</b>						
	(1) Current tax	-	-	-	-	-	-
	(2) Deferred tax	-	-	-	-	-	-
IX	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>237.63</b>	<b>208.70</b>	<b>47.87</b>	<b>446.33</b>	<b>229.03</b>	<b>582.67</b>
X	Profit/(loss) from discontinued operations	-	-	-	-	-	-
XI	Tax expenses of discontinued operations	-	-	-	-	-	-
XII	<b>Profit/(loss) from Discontinued operations (after tax) (X-XI)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XIII	<b>Profit/(loss) for the period (IX+XII)</b>	<b>237.63</b>	<b>208.70</b>	<b>47.87</b>	<b>446.33</b>	<b>229.03</b>	<b>582.67</b>
	<b>Other Comprehensive Income</b>						
	A. (i) Items that will not be reclassified to profit or loss	(13.06)	-	-	(13.06)	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss or loss	-	-	-	-	-	-
XV	<b>Total Comprehensive Income for the period (XIII+XIV)Comprising Profit (Loss) and Other.comprehensive Income for the period )</b>	<b>224.58</b>	<b>208.70</b>	<b>47.87</b>	<b>433.27</b>	<b>229.03</b>	<b>582.67</b>
XVI	<b>Earnings per equity share (for continuing operation):</b>						
	(1) Basic	0.95	0.88	0.20	1.83	0.97	2.46
	(2) Diluted	0.95	0.88	0.20	1.83	0.97	2.46
XVII	<b>Earnings per equity share (for discontinued operation):</b>						
	(1) Basic	-	-	-	-	-	-
	(2) Diluted	-	-	-	-	-	-
XVIII	<b>Earning per equity share (for discontinued &amp; continuing operation)</b>						
	(1)Basic	0.95	0.88	0.20	1.83	0.97	2.46
	(2) Diluted	0.95	0.88	0.20	1.83	0.97	2.46

- The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee on 11.11.2021 and subsequently approved by the Board of Directors at their Meeting held on 12.11.2021
- The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.
- The above figures have been regrouped and Re-arranged Wherever considered necessary
- Being the Second Quarter of the year, Figures of the Quarter ended 30th September 2021 and Year to date for this Quarter are the balancing figures of the Year to date Figures.
- Due to technical delays in the updation in line with the production process in the SAP system, the Company has not valued inventories on the basis of IND AS 2 principles. the same would be streamlined to comply with the standard by the end of Current Financial Year and the resultant impact if any would be quantified appropriately .
- The Company has provided the entire Gratuity liability as on 30th September 2021 in the books during the current period to the extent of Rs. 267.99 Lakhs, of which Rs. 196.53 Lakhs pertains to the earlier years has been shown under Exceptional Items and Rs. 13.06 Lakhs which was gain /loss on actuarial Valuation has been shown under other Comprehensive Income and the Balance of Rs. 58.40 Lakhs has been charged during the current period.
- The impact arising out of COVID-19 Pandemic on the future results of the Company will depend on developments, that are highly uncertain, including among other thing, any new information concerning the severity of the COVID-19 pandemic and any action to contain its spread or mitigate its impact whether government mandated or elected by the Company. The Company will continue to closely monitor any material changes in future economic conditions.

Place: Chennai  
Date: 12.11.2021

For BAFNA PHARMACEUTICALS  
LIMITED  
  
(S. HEMALATHA)  
Whole Time Director  
DIN :02714329



BAFNA PHARMACEUTICALS LIMITED ( CIN L24294TN1995PLC030698)

Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Standalone Balance Sheet as on

( Rs. In Lakhs)

Particulars	Stand Alone		
	As at 30th September 2021	As at 30th September 2020	As at 31 st March 2021
	Unaudited	Unaudited	Audited
<b>ASSETS</b>			
Non-Current Assets			
(a) Property, Plant and Equipment	3,711.17	3,452.76	3,596.64
(b) Capital Work-in-Progress	196.72	48.83	83.13
(c) Goodwill			
(d) Other Intangible Assets			
(e) Financial Assets			
(i) Investments	-		-
(ii) Trade Receivables			
(iii) Loans			
(iv) Other financials assets			
(g) Other Non-Current Assets			
<b>Total Non-Current Assets</b>	<b>3,907.89</b>	<b>3,501.59</b>	<b>3,679.77</b>
Current Assets			
(a) Inventories	1,875.55	1,374.18	1,544.34
(b) Financial Assets			
(i) Investments			
(ii) Trade Receivables	1,870.31	1,169.19	955.95
(iii) Cash and Cash Equivalents	72.38	122.07	180.37
(iv) Bank balance other than mentioned above			
(v) Loans			
(vi) Other financials assets			-
(c) Other Current Assets	1,619.71	1,267.80	2,286.16
(d) Assets classified as held for sale			
<b>Total Current Assets</b>	<b>5,437.95</b>	<b>3,933.24</b>	<b>4,966.82</b>
<b>Total Assets (1+2)</b>	<b>9,345.84</b>	<b>7,434.83</b>	<b>8,646.59</b>
<b>EQUITY AND LIABILITIES</b>			
(a) Equity Capital	2,365.63	2,365.63	2,365.63
(b) Other Equity	4,131.36	2,958.03	3,311.48
(c) Equity Share Warrants			
Equity Attributable to Equity Shareholders	<b>6,496.99</b>	<b>5,323.67</b>	<b>5,677.11</b>
(d) Non controlling Interests	-	-	-
<b>Total Equity</b>	<b>6,496.99</b>	<b>5,323.67</b>	<b>5,677.11</b>
Liabilities			
(a) Non-Current Liabilities			
(i) Financial Liabilities			
- Borrowings	304.56	-	250.00
- Trade Payable			
- Other Financial Liabilities	227.67	354.60	278.60
(ii) Provisions			
(iii) Deferred Tax Liabilities (Net)			
(iv) Other non-current liabilities	206.53	10.00	10.00
<b>Total Non-Current Liabilities</b>	<b>738.76</b>	<b>364.60</b>	<b>538.60</b>
(b) Current Liabilities			
(i) Financial Liabilities			
- Borrowings			
- Trade Payable	1,859.67	1,471.43	1,069.16
- Dues to micro and small enterprises			
- Dues to Others			
- Other Financial Liabilities	-		1,000.00
(ii) Other Current Liabilities	250.43	275.15	361.72
(iii) Provisions			
(iv) Current Tax Liabilities (net)			
<b>Total Current Liabilities</b>	<b>2,110.10</b>	<b>1,746.58</b>	<b>2,430.87</b>
<b>Total Liabilities</b>			
<b>Total Equity and Liabilities</b>	<b>9,345.84</b>	<b>7,434.83</b>	<b>8,646.59</b>

For BAFNA PHARMACEUTICALS LIMITED

(S.HEMA LATHA)

Whole Time Director

DIN : 02714329

Place : Chennai

Date : 12.11.2021





**BAFNA PHARMACEUTICALS LIMITED ( CIN L24294TN1995PLC030698)**  
**Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001**  
**Standalone Cash flow Statement** ( Rs. In Lakhs)

Particulars	Stand Alone		
	As At 30th September 2021	As At 30th September 2020	As at 31 st March 2020
	Unaudited	Unaudited	Audited
<b>Cash Flow from Operating Activities:</b>			
Net Profit Before Tax and Including Exceptional Items	839.39	229.03	582.67
<b>Adjustments for:</b>			
Depreciation	288.37	196.09	447.82
Interest Paid	21.52	3.77	8.86
Interest Received	(3.48)		(3.95)
Sundry Balances Written Back			(28.35)
Other Income	(30.75)	(40.03)	(41.90)
Lease Rent Received	(0.41)	(0.23)	(0.74)
Exceptional items- Impact of impairment of Financial assets	(196.53)	-	
Other Comprehensive Income	(13.06)		
<b>Operating Profit before Working Capital Changes</b>	<b>905.05</b>	<b>388.62</b>	<b>964.41</b>
<b>Adjustment For:</b>			
[Increase]/decrease in Inventories	(331.21)	(232.94)	(403.09)
[Increase]/decrease in Trade Receivables	(914.36)	(565.71)	(352.47)
[Increase]/decrease in Short Term Loans and Advances	666.45	(272.46)	(1,290.82)
Increase/[decrease] in Trade Payables	790.51	217.29	(184.98)
Increase/[decrease] in Other Current Liabilities	(111.28)	(170.50)	(93.94)
Cash generated from Operation	<b>1,005.15</b>	<b>(635.70)</b>	<b>(1,360.89)</b>
Less: Tax Paid	-	-	-
<b>Net Cash Used in Operating Activity (A)</b>	<b>1,005.15</b>	<b>(635.70)</b>	<b>(1,360.89)</b>
<b>Cash Flow from Investing Activities:</b>			
Purchase of Fixed Assets	(228.12)	(179.57)	(609.47)
Other Income	30.75	40.03	41.90
Interest Received	3.48	-	3.95
Sundry Balances Written Back	-	-	28.35
Lease Rent received	0.41	0.23	0.74
Changes in Long Term Loans and Advances			
Change in Other Non- Current Assets			
<b>Net Cash used in Investing Activities (B)</b>	<b>(193.47)</b>	<b>(139.30)</b>	<b>(534.54)</b>
<b>Cash Flow from Financing Activities</b>			
Issue of Shares, Warrants & Application Activities	-	-	-
Proceeds of Investment Subsidy ( State Govt Subsidy)	98.21	-	-
Changes in Long Term Borrowings	54.56	52.84	250.00
Changes in Short Term Borrowings	(1,050.93)	-	986.84
Interest Paid	(21.52)	(3.77)	(8.86)
<b>Net Cash from Financing Activities (C)</b>	<b>(919.68)</b>	<b>49.08</b>	<b>1,227.98</b>
<b>Net Increase/ [Decrease] in Cash or Cash Equivalents [A+B+C]</b>	<b>(107.99)</b>	<b>(725.94)</b>	<b>(667.64)</b>
<b>Opening Balance of Cash &amp; Cash Equivalents</b>	<b>180.37</b>	<b>848.01</b>	<b>848.01</b>
<b>Closing Balance of Cash &amp; Cash Equivalents</b>	<b>72.38</b>	<b>122.07</b>	<b>180.37</b>

**Note :**

Pursuant to Insertion of New Clause under Regulation 33, Sub-regulation (3), the company has prepared Standlone Cash Flows statement for the half Year Ended 30th September 2021. The Statement of Cash Flows for the half Year ended 30th September 2021, as reported in the statement have been approved by the Company's Board of Directors.

Place : Chennai  
Date : 12.11.2021



For BAFNA PHARMACEUTICALS LIMITED

*(Signature)*  
(S.HEMA LATHA)  
Whole Time Director  
DIN : 02714329





**R. SATHYANARAYANAN & Co.**  
**CHARTERED ACCOUNTANTS**

Ph.: 28112450 / 42132674  
E-mail:rsathyas@gmail.com

Partners:

**CA R. SATHYANARAYANAN**, B.Com., F.C.A., ISA (ICAI),  
**CA R. SATHYANARAYAN**, B.Com., F.C.A., ISA (ICAI),

# 2 (Old # 21), Ground Floor,  
Lakshmipuram 2nd Street,  
Royapettah, Chennai - 600 014.

Independent Auditor's Review Report on Quarterly unaudited and year to date financial results of BAFNA PHARMACEUTICALS LIMITED pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended

The Board of Directors  
Bafna Pharmaceuticals Limited  
No.299, Thambu Chetty Street, Chennai-600 001

1. We have reviewed the accompanying statement of unaudited financial results of M/s. Bafna Pharmaceuticals Limited for the quarter ended 30<sup>th</sup> September 2021 and year to date results for the period from 01 April 2021 to 30 September 2021 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.







**R. SATHYANARAYANAN & Co.**  
**CHARTERED ACCOUNTANTS**

Ph.: 28112450 / 42132674  
E-mail:rsathyas@gmail.com

Partners:

**CA R. SATHYANARAYANAN**, B.Com., F.C.A., ISA (ICAI),  
**CA R. SATHYANARAYAN**, B.Com., F.C.A., ISA (ICAI),

# 2 (Old # 21), Ground Floor,  
Lakshmipuram 2nd Street,  
Royapettah, Chennai - 600 014.

4 . Based on our review conducted as above, except for: *Continuing irregularities since Financial year 2020-21: (a) Valuation of Work-in-progress and Finished goods as on 30<sup>th</sup> September 2021 not computed as per principles laid down in IND AS 2, (b) Unresolved mismatch in respect of ITC (Input tax credit) between books of accounts and GSTR2A, the taxable value of which was Rs 53 lakhs, (c) SAP system not being fully online at Grantylon factory in respect of Stores/production processes and (d) Fixed Asset register not being maintained in SAP as prescribed under Schedule II of the Companies Act besides non-compliance in respect of IND AS 16, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed or that it contains any material misstatement.*

*Our opinion is modified in respect of the above*

UDIN: 21028377AAAACB3393

Place: Chennai

Date : 12.11.2021

**For R. SATHYANARAYANAN & CO.**  
Chartered Accountants  
ICAI Regn. No. 003656S

Partner  
R. Sathyanarayan  
M. No. 028377

**R. SATHYANARAYANAN & CO.**  
Chartered Accountants  
No. 2, (Old No. 21), Ground Floor,  
Lakshmipuram 2nd Street,  
Royapettah, Chennai - 600 014.